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Abstract
Background: Clinical practice guidelines give recommendations about what to do in various medical situations, 
including therapeutical recommendations for drug prescription. An effective way to computerize these 
recommendations is to design critiquing decision support systems, i.e. systems that criticize the physician's 
prescription when it does not conform to the guidelines. These systems are commonly based on a list of "if conditions 
then criticism" rules. However, writing these rules from the guidelines is not a trivial task. The objective of this article is 
to propose methods that (1) simplify the implementation of guidelines' therapeutical recommendations in critiquing 
systems by automatically translating structured therapeutical recommendations into a list of "if conditions then 
criticize" rules, and (2) can generate an appropriate textual label to explain to the physician why his/her prescription is 
not recommended.
Methods: We worked on the therapeutic recommendations in five clinical practice guidelines concerning chronic 
diseases related to the management of cardiovascular risk. We evaluated the system using a test base of more than 
2000 cases.
Results: Algorithms for automatically translating therapeutical recommendations into "if conditions then criticize" 
rules are presented. Eight generic recommendations are also proposed; they are guideline-independent, and can be 
used as default behaviour for handling various situations that are usually implicit in the guidelines, such as decreasing 
the dose of a poorly tolerated drug. Finally, we provide models and methods for generating a human-readable textual 
critique. The system was successfully evaluated on the test base.
Conclusion: We show that it is possible to criticize physicians' prescriptions starting from a structured clinical 
guideline, and to provide clear explanations. We are now planning a randomized clinical trial to evaluate the impact of 
the system on practices.
Background
Clinical practice guidelines (CPGs) provide recommen-
dations for the diagnosis and treatment of numerous dis-
eases; they have been proved to be helpful for physicians
[1]. However, guidelines printed on paper are difficult to
use efficiently during medical consultation [2] and guide-
line-based learning programmes are not sufficient [3].
This has led to the development of decision support sys-
tems (DSSs) based on CPGs. Two reviews reveal that
DSSs improved clinical practices in 64% [4] and 68% [5]
of trials, and the use of a DSS was identified as one of the
factors critical for success in improving healthcare for
chronic disease [6,7]. In particular, critiquing DSSs,
requiring little or no intervention from the physician,
provide criticism to the physician whenever his/her activ-
ity (e.g. drug prescriptions) is considered by the DSS as
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Page 2 of 14non-adequate in the light of current medical knowledge
[8]. Critiquing DSSs have been shown to have a greater
impact than on-demand DSSs on practice [4,9].
A first approach for designing critiquing DSSs consists
in modelling the situations and actions that should be
criticized, typically using a set of "if conditions then criti-
cism" rules. It has been shown that if-then rules are satis-
factory for critiquing drug prescriptions on the basis of
the therapeutical recommendations expressed in many
CPGs [10]. Critiquing DSSs based on "if conditions then
criticism" rules have been proposed for various medical
problems, including asthma [11,13], dyslipaemia [9,13],
antibiotic prescriptions [13], and test ordering [14,15].
However, building the knowledge base requires convert-
ing CPG recommendations into these "if conditions then
criticism" rules. This task is difficult because:
1. it requires both logical and medical expertise, and
therefore it needs input from both physicians and
computer scientists,
2. it requires to take into account medical knowledge
that is implicit in the CPGs (e.g. CPGs do not explic-
itly state that it is possible to reduce the dose of a drug
to lower the adverse effects it causes),
3. there is not one-to-one mapping between recom-
mendations and criticisms; for instance the following
recommendation "at the first stage of diabetes type 2,
prescribe metformin as first-line treatment, and an
alpha-glucosidase inhibitor (AGI) as second-line
treatment" leads to three possible criticisms (see table
1):
(a) if AGI is prescribed as first-line treatment:
"AGI is a second-line treatment; metformin is rec-
ommended as first-line treatment",
(b) if another drug is prescribed as first-line treat-
ment: "other drugs are not recommended for the
patient; metformin is recommended as first-line
treatment",
(c) if another drug is prescribed as second-line
treatment: "other drugs are not recommended for
the patient; metformin is recommended as first-
line treatment and AGI as second-line".
Despite the two first criticisms lead to the same recom-
mendation (prescribe metformin), the criticism displayed
to the physician should not be the same, since the reasons
and the explanations justifying the alert are different.
In ASTI 1 and ASTI 2 [16,18], we proposed another
approach for establishing critiquing DSSs that uses a
structured model of the CPG therapeutical recommenda-
tions. The system first determines the set of drug pre-
scriptions recommended for the patient, and then raises
an alert if the physician's prescriptions are not in this set.
During preliminary tests, this approach efficiently
detected physician's prescriptions that did not conform to
the CPG [19]. However, it failed to generate a textual cri-
tique explaining to the physician why the drugs he/she
prescribed did not conform, because (1) the first part of
the reasoning process (determining the drugs recom-
mended for the patient) does not take into account the
physician's prescription, and (2) the knowledge model
was limited to the representation of recommendations,
which was insufficient to generate a meaningful critique
(see difficulties 2 and 3 above). For instance, when apply-
ing the recommendation of the previous example to the
prescription of an AGI for a patient as first-line treat-
ment, the system deduces that the only recommended
prescription is metformin. As the physician's prescription
is different, a critique is generated. However, the textual
critique is limited to "metformin is recommended as first-
line treatment", without being able to state that "AGI is a
second-line treatment" as above.
Table 1: Various possible situations for an example of therapeutical recommendation.
physician proposed 
metformin (first-line 
treatment)
physician proposed alpha-
glucosidase inhibitors (AGI, 
second-line treatment)
physician proposed any 
other treatment
patient at the stage of first-line 
treatment
OK criticism: AGI should be 
prescribed only as second-line 
treatment. Guideline 
recommends metformin as 
first-line treatment.
criticism: Sulfonamides, 
glinides and glitazones are not 
recommended. Guideline 
recommends metformin as 
first-line treatment.
patient at the stage of second-
line treatment
OK (e.g. with a different dose; 
preventing the represcription 
of ineffective or poorly 
tolerated treatments is the 
task of other 
recommendations)
OK criticism: Sulfonamides, 
glinides and glitazones are not 
recommended. Guideline 
recommends metformin as 
first-line treatment, and AGI as 
second-line.
The table shows the six possible cases for a given patient and physician prescription with regard to the recommendation "prescribe 
metformin as first-line treatment and alpha-glucosidase inhibitor (AGI) as second-line".
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Page 3 of 14The objective of this article is to present and evaluate a
drug prescription critiquing system that combines the
two approaches presented above, and aims at (1) facilitat-
ing the creation of new knowledge bases, with a system
designed to support the therapeutical recommendations
of many, if not all, CPGs, and (2) being able to generate a
clear and appropriate textual critique that explains to the
physician why his/her prescriptions do not conform to
the CPG. The knowledge base is composed of (a) specific
recommendations that directly match the CPG recom-
mendations, enriched with textual labels for generating
the critiques, and (b) generic recommendations that
model the implicit, CPG-independent, medical knowl-
edge required for the critiquing process. This knowledge
base is then automatically transformed into a set of exe-
cutable "if conditions then criticism" rules. To show that
it is easy to write knowledge bases and that the system is
generic, we applied it to the therapeutic recommenda-
tions of five CPGs concerning chronic diseases related to
cardiovascular risk.
The article first presents the ASTI project, as part of
which this study was carried out. Then we present the
methods for selecting the CPGs, designing the models,
writing the algorithms, and evaluating the system. The
results section describes the system by presenting the
models, the algorithms for translating recommendations
into "if conditions then criticism" rules, and the generic
recommendations, and gives the results of the implemen-
tation of the five CPGs and the evaluation for these
CPGs. Finally, we consider the value and the limitations
of the DSS we have developed.
The ASTI project
The ASTI project [16,18] aims to improve therapeutic
care for patients with chronic diseases, through the
design of generic DSSs which may help physicians to take
into account the therapeutic recommendations of rele-
vant CPGs. The global architecture of the ASTI project is
shown in figure 1. The project includes three comple-
mentary modules that correspond to various steps in
medical care [20]. The first module is the guiding module
which provides the physician with recommended treat-
ments through an hypertextual navigation within the
knowledge base [21]. The second module, the critiquing
module, is for validating prescriptions. It is automatically
activated when the physician writes a prescription; it gen-
erates an alert when the prescription does not conform to
the CPG. This module was inspired by the reminder sys-
tems successfully developed over recent decades for pre-
venting drug interactions. The third module concerns
patient follow-up; it lists various clinical and biological
variables for the patient, with additional temporal data,
such as when the physician should prescribe biological
tests, according to the CPG recommendations. This arti-
cle focuses on the critiquing module. The ASTI project
has evolved over the last few years: ASTI 1 and 2 were ini-
tially aimed at hypertension and diabetes type 2, and
ASTI 3 now aims to generalize the progress made to
other CPGs.
Methods
Design methods
We started with the ASTI 2 critiquing module, which
provided a general architecture for the DSS. The ASTI 2
critiquing module is a rule-based system, with (a) a data-
enriching component, which computes derived patient
data from data available in the patient files, e.g. comput-
ing the Body Mass Index (BMI) from the height and the
weight, (b) an inference engine, and (c) two knowledge
bases implementing the French CPGs for hypertension
[22] and type 2 diabetes [23].
Selecting guidelines
We worked on five CPGs published by the French health
authorities for hypertension [22], type 2 diabetes [23],
tobacco addiction [24], dyslipaemia [25] and atrial fibril-
lation [26]. These CPGs were chosen because they all
relate to the cardiovascular risk and cover various aspects
of the clinical care, e.g. the tobacco addiction CPG
involves short-duration treatments whereas the other
CPGs involve life-long treatments.
Modelling "if conditions then criticism" rules
"If conditions then criticism" rules are executed by the
inference engine. Various elements were considered for
rule conditions, inspired by the ASTI 2 critiquing mod-
ule: (a) the patient's clinical condition (including current
and past diseases and physiological states), (b) biological
test results for the patient, and (c) the patient's therapeu-
tic history (i.e. the list of past and current prescriptions),
including treatment outcomes (i.e. treatment efficacies
and drug tolerances). In the CPGs, clinical and biological
conditions are relatively simple. Treatments expressed in
CPGs are more complex, because many levels of granu-
larity are used. We started from the ASTI 2 treatment
model [18], and we extended this model to represent not
only precise treatments, but also what we call hereafter
treatment patterns of a lower granularity, such as "any
bitherapy", "metformin in bitherapy" or "any past treat-
ment including metformin with poor tolerance".
Modelling CPG recommendations
In the ASTI 3 critiquing module knowledge base, CPG
recommendations are written manually from the guide-
lines; they aim at being easy to write and as close as possi-
ble to the CPG.
We extracted all therapeutic recommendations from
the five CPGs, and for structuring them we designed a
simple model inspired by the plan-based models in the
literature. Each recommendation can lead to one or more
criticisms. For instance, if we consider the recommenda-
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alpha-glucosidase inhibitor (AGI) as second-line", there
are two patient stages (patient requiring first-line treat-
ment and patient requiring second-line treatment) and
three treatments the physician can prescribe (metformin,
AGI, and any other), and thus six possible situations,
shown in table 1. Three of them lead to a criticism, all
three criticisms being different. Therefore, we enriched
the CPG recommendation model with attributes for
modelling the textual criticisms.
Many guideline recommendations are complex and
involve several lines of treatment. Recommendations
with several lines of treatments could theorically be split
in simpler recommendations, though it is not always
desirable; for instance "prescribe metformin as first-line
treatment" and "prescribe AGI as second-line treatment".
However the second of these recommendations cannot
be interpreted alone: "second-line treatment" is actually
relative to the first recommendation and actually means
"if metformin cannot be prescribed or was not satisfying".
Therefore, we didn't try to split recommendations.
Writing generic recommendations
Pieces of medical knowledge that are both well-known by
physicians and not specific to the disease addressed by
the CPG are usually implicit in guidelines. For example,
CPGs do not explicitly state that it is possible to reduce
the dose of a drug to lower the adverse effects it causes.
However, such medical knowledge is necessary for cri-
tiquing a prescription.
Consequently, we wrote generic recommendations for
capturing this implicit knowledge. The criteria for a
generic recommendation are the following: (a) it is inde-
pendent of CPG, (b) it applies to at least three of the
knowledge bases we developed for the five CPGs listed
above, and (c) it is likely to apply to other CPGs. We
required at least three occurrences (criterium b), because
many recommendations are guideline-specific, even if
they do not involve drugs or clinical contexts related to
the guideline's disease, e.g. when a monotherapy has no
effect at all, the guideline for arterial hypertension recom-
mends to try another drug, but not to prescribe a bither-
apy; however this recommendation is not found in the
other guidelines, and therefore it cannot be considered as
generic. By default, generic recommendations apply to all
knowledge bases; for some of them it is possible to spec-
ify exceptions, e.g. lowering the dose of the bupropion is
not possible, due to its narrow therapeutic range.
Designing algorithms for transforming recommendations 
into "if conditions then criticism" rules
The final step in building the ASTI 3 critiquing module
was to design algorithms for automatically transforming
both CPG and generic recommendations into "if condi-
Figure 1 Global architecture and components of the ASTI project.
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sibility study to ensure that such translation was possible.
In this study, a set of "if conditions then criticism" rules
equivalent to the recommendations for antihypertensive
monotherapy were written manually. We chose antihy-
pertensive monotherapy because it contains substantial
complexity in a small subset of a CPG. Then, we wrote
algorithms for automating the translation of recommen-
dations into "if conditions then criticism" rules. One of
the most complex types of recommendations follows the
pattern "prescribe X as first-line treatment, Y as second-
line treatment,..."; an example of such recommendations
is given in table 1. We generalized this situation to N line
of treatments.
Some of the generic recommendations are translated
into "if conditions then criticism" rules that are totally
independent from the content of the CPG (e.g. a rule cri-
tiquing the interruption of an effective and well-tolerated
treatment). Some other generic recommendations lead to
algorithms that generate one "if conditions then criticism"
rule for each pharmaco-therapeutic class of drug or for
each treatment recommended by the CPG (e.g. a rule cri-
tiquing the represcription of metformin if metformin has
been poorly tolerated in the past). Finally, the remaining
generic recommendations were taken into account when
writing the various algorithms, but were not used to pro-
duce "if conditions then criticism" rules directly.
The complete list of algorithms is reported in the
results section.
Software implementation methods
The ASTI 3 critiquing module was written using the
Python programming language. The therapeutic history
was coded using the ATC (Anatomical Therapeutic
Chemical) drug classification.
Testing and evaluation methods
Three types of tests were performed to ensure the confor-
mity of the DSS recommendations to the CPGs content.
In all tests, we considered the guidelines as the "gold-
standard", and thus we didn't investigate potential error
in the guidelines.
First, a test base was written manually for each CPG.
The test base was built by creating patient profiles that
covered the various clinical situations and types of treat-
ment. Then for each patient profile, we generated several
test cases corresponding to the prescription of various
treatments to that patient: one test case per treatments
recommended by the CPG, and five test cases with ran-
domly-generated non-recommended treatments, in
order to verify that these non-recommended treatments
are criticized as expected.
Second, for the diabetes type 2, tobacco addiction, dys-
lipaemia, atrial fibrillation and thrombo-embolic risk
knowledge bases, a new quasi-exhaustive verification
method was used [19]; this method considers the DSS as
a black box, and tries to regenerate the CPG knowledge
from the DSS. It consists in three steps: (1) Generating an
almost exhaustive set of the possible DSS input vectors.
This was achieved by considering a limited number of
patient attributes (e.g. age, sex, current treatment,...) and
a limited number of possible values for each attribute (e.g.
14, 18, 35, 75 years for age), and then generating all the
possible combinations of attribute values. Finally, the DSS
was run to determine the output for each input vector. (2)
Extracting knowledge from the set of (input vector, out-
put result) pairs. We used the C4.5 algorithm to generate
a decision tree; pruning was disabled to keep 0% of error
in the tree. (3) Comparing the decision tree generated
with the original CPG, to check that the treatments rec-
ommended by the tree conform to the CPG, and that
none of the recommendations included in the CPG are
missing from the tree. This method was not applied to
the hypertension knowledge base, because the number of
possible input vectors was too high, and the decision tree
would be far too big to be human-readable. Third, the
knowledge bases were reviewed manually by a physician,
who was asked to compare them to the content of the
original CPGs. The physician was briefly introduced to
the functioning of the ASTI 3 critiquing module. The rec-
ommendations in the knowledge bases were rephrased
into an equivalent text in natural language, before being
reviewed by the physician, e.g.: "if the treatment pre-
scribed is a monotherapy and HbA1c ≤ 6.5%, then met-
formin should be prescribed as first-line treatment, and
AGI as second-line treatment".
Results
Description of the ASTI 3 critiquing module
The general architecture of the ASTI critiquing module is
shown in figure 2. The ASTI critiquing module was
linked to éO Généraliste®, a French Electronic Patient
Record (EPR) which provides the therapeutic history, the
biological results and some clinical conditions of the
patient. Additional dialog boxes were added to éO Gén-
éraliste® to ask for treatment outcomes and further infor-
mation about patient clinical condition. The ASTI 3 data
enriching component is responsible for linking the cri-
tiquing module to the EPR. In particular, the data enrich-
ing component determines the indication of each
prescribed drug, from the drug's recommended indica-
tion and the prescribed dose (e.g. for aspirin, which have
different indication depending on the dose), and regroups
the drugs by indication, possibly duplicating them when a
drug has several indications (e.g. beta-blocking agents are
indicated for both arterial hypertension and atrial fibrilla-
tion). Finally, the critiquing module is run for each indi-
cation found in the prescription.
The data enriching component is also in charge of com-
puting various medical abstractions, such as relative
Lamy et al. BMC Medical Informatics and Decision Making 2010, 10:31
http://www.biomedcentral.com/1472-6947/10/31
Page 6 of 14posologies (i.e. has the drug dose been increased or low-
ered in the new prescription?). A few elements are
required for critiquing the prescription, but are usually
not present, or only in free text, in the EPR: drug toleran-
cies, treatment efficacy, and some clinical conditions (e.g.
late discovery of diabetes type 2). For these elements, dia-
log boxes have been added to the EPR, for asking them to
the physician. The values of these elements are then
stored in the EPR for future uses.
In the following subsections, we describe the various
parts of the critiquing module.
"If conditions then criticism" rule model and treatment 
pattern model
As stated in the introduction, "if conditions then criti-
cism" rules are not supposed to be manually written, but
automatically generated from a model of the CPG. Rule
conditions can include clinical elements, represented by
simple (attribute, operator, value) triplets (e.g. (age, infe-
Figure 2 Architecture and data sources of the ASTI critiquing module.
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ments, represented by treatment patterns. AND, OR and
NOT logical operators can be used to combine several
elements in conditions, and these operators can be
nested.
Treatment patterns are queries that can be read as: "it
exists in the therapeutic history at least one treatment
that matches the pattern X". The treatment pattern
model is shown in figure 3; this model can represent
treatment of various levels of granularity, from a specific
treatment to classes of treatment (e.g. bitherapy, insulino-
therapy) and partially defined treatments (e.g. any treat-
ment including metformin). It contains information
about (a) drug classes (using the ATC code; the model
allows to define a drug class using several codes because
some pharmacological classes cannot be represented by a
single ATC code, e.g. glinide), (b) dose and form, (c)
changes from the preceding treatment (dose change,
form change, INN change), (d) drug tolerance and treat-
ment efficacy for the patient (these items of information
are specified by the physician in ASTI 3 dialog boxes), (e)
treatment status (past treatment, current treatment or
treatment proposed by the physician and being validated
by the critiquing module).
The criticism part of the rules is simply represented by
a textual label to be presented to the physician.
CPG recommendation model
We structured the therapeutical recommendations found
in CPGs. Our work with five CPGs led us to distinguish
three types of recommendations: (1) "one should pre-
scribe" recommendations give a list of recommended
treatments. There can be several lists corresponding to
first, second,... Nth lines of treatments, and we associate
line N + 1 to any other non-recommended treatment (the
patient is never considered to be at the stage of treatment
of line N + 1, but the treatment prescribed by the physi-
cian can be a treatment of line N + 1, if it does not match
any other line), (2) "one should not prescribe" recommen-
dations advise to not prescribe some treatments in a
given situation, and (3) "treatments of increasing power"
recommendations state that some treatments are more
effective than others. The recommendation model is pre-
sented in figure 4; conditions and treatment patterns are
the same as those used in "if conditions then criticism"
rules.
In this model, "criticism label" attributes are used for
modelling the textual criticisms shown to the physician,
usually using excerpts of the CPG. For "one should pre-
scribe" recommendations, the criticism label is split into
three parts: (1) the explanation criticism label explains
why a treatment of a given line should not be prescribed
to a patient requiring a treatment of a lower line (e.g. a
second-line treatment to a patient at the stage of first-line
treatment), (2) the advice criticism label states the recom-
mended treatments for patients require a treatment of a
given line, and (3) the reference criticism label gives bibli-
ographic references (e.g. the page number in the CPG).
There are one advice and explanation criticism labels for
each line of treatment in the recommendation. The criti-
cism shown to the physician will be the concatenation of
the explanation criticism label of the line of the treatment
proposed by the physician, the advice criticism label of
the line at which the patient is, and the reference criti-
cism label.
Figure 3 The treatment pattern model, represented in UML. The elements that were added to extend the treatment model into a treatment pat-
tern model are shown in red and italics. INN means "International Nonproprietary Name".
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in the recommendation, thus line 3 is the "any other treat-
ment" line (the last column). In the three criticisms, the
first sentence is the explanation part and the second the
advice part (the reference part is not shown). As a result
of the model, advice criticism labels are the same in each
line, and explanation criticism labels are the same in each
column.
Generic recommendations
Eight generic recommendations were found during the
design of the ASTI 3 critiquing module; they are listed in
table 2. These recommendations correspond to a sort of
"medical common sense"; they are related to the treat-
ment and apply to many, and in some case all, medical sit-
uations. They are either independent from CPG, or they
depend only on the list of pharmacological drug classes
or treatments that the CPG recommends. Generic rec-
ommendation #1 leads to continuing an effective well-
tolerated treatment: this is logical for chronic diseases.
Generic recommendations #2 to #4 are related to dose;
they provide generic guidance but can be overridden by
CPG-specific rules, e.g. tolerance of some drugs is not
dose-dependent. Generic recommendations #5 and #6
prevent represcription of a treatment that has failed in
the past; we limited generic recommendation #6 to the
recent past because a treatment that was ineffective years
ago may be effective in the future if the patient's condi-
tions are different (e.g. if the patient's weight has changed
substantially). Generic recommendation #7 leads to apply
the recommendations for poor tolerance when the treat-
ment is both ineffective and poorly tolerated, because in
case of poor tolerance, the patient's adherence to the
treatment is often low and therefore the efficacy of the
treatment cannot be rigorously evaluated. Finally, generic
recommendation #8 prevents the simultaneous prescrip-
tion of two drugs of the same pharmacological class (e.g.
two beta-blocking agents).
Algorithms for transforming recommendations into "if 
conditions then criticism" rules
We wrote algorithms for transforming CPG and generic
recommendations into "if conditions then criticism"
rules. The conditions of the rules generated include the
conditions from the recommendations (labelled "(condi-
tion)" below) and additional conditions.
-For a "one should not prescribe" recommendation,
the algorithm is trivial and generates one rule: "if
(conditions) and (the treatment proposed by the phy-
sician is the treatment to not prescribe) then criti-
cism".
-For a "treatment of increasing power" recommenda-
tion with N power levels, the algorithm generates N -
1 rules: "if (conditions) and (the proposed treatment is
a treatment of power level X) and (there is in the ther-
apeutic history an ineffective treatment of power level
Y > X) then criticism" (for 2 ≤ X ≤ N).
-For a "one should prescribe" recommendation with N
lines of treatments (line N + 1 being associated to any
other treatment), the algorithm generates 
rules. We consider that the patient is at the stage of
line X if and only if:
*when X = 1, "there is no ineffective or poorly tol-
erated treatment of any line in the therapeutic his-
tory",
*when 2 ≤ X ≤ N - 1, "(there is no ineffective or
poorly tolerated treatment of line ≥ X in the thera-
peutic history) and (there is an ineffective or
N N( )+1
2
Figure 4 The recommendation model, represented in UML. Attributes modelling the textual criticism are shown in red and italics.
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# Generic recommendations Hyp. Diab. Dys. Tob. Atr. Thr. Exceptions
1 If the current treatment is effective, well-tolerated and 
recommended by the CPG, it should be continued
      12/113
2 If the current treatment is ineffective, the dose can be 
increased
      2/113
3 If the current treatment is too effective, the dose can be 
decreased
  n.a. n.a. n.a.  0/113
4 If a drug of the current treatment is poorly tolerated, the dose 
can be decreased
      1/43
5 If a treatment was not effective in the recent past, it should 
not be prescribed again
      15/113
6 If a drug was not tolerated in the past, it should not be 
prescribed again
      0/43
7 If a treatment is both poorly tolerated and ineffective, apply 
the recommendations for poor tolerance
      0/113
8 Two drugs of the same pharmaco-therapeutic class should 
not be prescribed in association
      6/43
Hyp.: hypertension, Diab.: type 2 diabetes, Dys.: dyslipaemia, Tob.: tobacco addiction, Atr.: atrial fibrillation, Thr.: thrombo-embolic risk.  
indicates that the recommendation is used for implementing the CPG,  that the recommendation is used with exceptions,  that the 
recommendation does not apply, and n.a. that the situation does not occur in practice. The exception column gives the rate of exceptions for 
each generic recommendations (number of exceptions/denominator; the denominator is either 43, the total number of drug classes, or 113, the 
total number of recommended treatments found in the five guidelines).
poorly tolerated treatment of line X - 1 in the
therapeutic history)",
*when X = N, "there is an ineffective or poorly tol-
erated treatment of line N - 1 or N in the thera-
peutic history".
The rules are: "if (conditions) and (the patient is at the
stage of line X) and (the proposed treatment is a treat-
ment of line Y) and (the proposed treatment is not a
treatment of line < Y) then criticism (explanation criti-
cism label for line Y + advice criticism label for line X +
reference criticism label)" (for 1 ≤ X ≤ N, for X + 1 ≤ Y ≤ N
+ 1).
We include "the proposed treatment is not a treatment
of line < Y" in conditions because, due to the various pos-
sible levels of granularity for expressing treatments, there
might be overlap between treatments from different lines.
E.g. in the recommendation "prescribe simvastatin or
pravastatin as first-line treatment, and any statin as sec-
ond-line treatment".
-Generic recommendation #1 leads to the rule: "if (the
current treatment conforms to the guideline, and is
effective and well-tolerated) and (the proposed treat-
ment includes an INN change, a dose change or a
form change) then criticism".
-Dose-related generic recommendations (#2, 3 and 4)
lead to three rules:
*"if (the current treatment is ineffective but well-
tolerated) and (the proposed treatment is a dose
reduction) then criticism"
*"if (the current treatment is poorly tolerated) and
(the proposed treatment is a dose increase) then
criticism"
*"if (the current treatment is too effective) and
(the proposed treatment is a dose increase) then
criticism". An example of a too-effective treat-
ment is an antivitamin K anticoagulant drug,
when the INR (International Normalized ratio) is
higher than the therapeutical range, i.e. the anti-
coagulant effect is too important, and the drug
dose should be reduced.
-For generic recommendation #5, we consider that a
past ineffective treatment should not be represcribed
if it has been stopped in the past. This leads to one
rule for each recommendable treatment T in the
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Page 10 of 14guideline: "if (the proposed treatment is a treatment
T) and (the therapeutic history includes an ineffective
treatment T within the last three years, which has not
been followed by another treatment T) then criti-
cism".
-Similarly, for generic recommendation #6, we con-
sider that a drug poorly tolerated in the past should
not be represcribed if it has been stopped in the past.
This leads to one rule for each pharmaco-therapeutic
class C in the guideline: "if (the proposed treatment
includes a drug of the pharmaco-therapeutic class C)
and (the therapeutic history contains a past treatment
including a poorly tolerated drug of the pharmaco-
therapeutic class C, which was followed by a treat-
ment that does not include a drug of the pharmaco-
therapeutic class C) then criticism".
-Generic recommendation #8 leads to one rule for
each pharmaco-therapeutic class C in the guideline:
"if (the proposed treatment includes two drugs of the
pharmaco-therapeutic class C) then criticism".
Description of the knowledge bases
It was possible to represent all therapeutic recommenda-
tions found in the five CPGs using the CPG recommen-
dation model. The CPG for atrial fibrillation included
recommendations for two clinical conditions: atrial fibril-
lation itself and thrombo-embolic risk; consequently, we
wrote a separate knowledge base for each. For both of
them, the CPG takes into account some clinical variables
that evolve very frequently (e.g. patient at fibrillation for
less than 48 hours) or that might not be available at the
time of prescription (e.g. the type of atrial fibrillation,
either paroxistic, permanent or persistent, is frequently
known a posteriori, since it depends on the presence of
recurrences in the next 7 days). Consequently, we wrote
partial knowledge bases that do not take these variables
into account. Table 3 shows the characteristics of the six
knowledge bases, and the generic recommendations
which apply in each knowledge base are given in table 2.
Additional file 1 gives examples of recommendations in
ASTI 3, and Additional file 2 shows examples of gener-
ated rules.
Inference engine
The inference engine is simple, most of the reasoning
being done by the algorithms described above. It per-
forms the following four steps:
(1) it executes the "if condition then criticism" rules
for the treatment proposed by the physician; if one or
more rules is triggered, the treatment does not con-
form to the knowledge base and an alert will be
issued,
(2) it generates a textual criticism by concatenating
the textual criticisms of all triggered rules,
(3) it generates a list of treatment suggestions, by exe-
cuting the "if condition then criticism" rules for all
recommendable treatments in the CPG, and retaining
only the treatments that do not trigger any rule,
(4) if the list of suggestions is empty, the rules are
relaxed to accept a second-line treatment for a patient
at the stage of first-line treatment (or a third-line
treatment for a patient at the stage of second-line
treatment, etc), and the inference engine restarts at
step 1. If the list of suggestions is still empty, the rules
can again be relaxed, to accept a third-line treatment
for patient at the stage of first-line treatment, and so
on. This situation occurs when a line of treatment
cannot be prescribed, e.g. because all the recom-
mended drugs are not tolerated by the patient; in that
case, the usual prescribing behaviour is to prescribe a
second-line (or third-line, etc) treatment. If the list of
suggestions is empty when relaxing the rules to the
maximum, then the CPG does not provide enough
information for making a decision (e.g. all the possible
treatments are contraindicated, poorly tolerated or
ineffective).
Testing and evaluation results
We first tested the ASTI critiquing module using a test
base involving 59 clinical cases and 652 test cases for
hypertension, 56 and 877 for type 2 diabetes, 31 and 348
for tobacco addiction, 31 and 256 for dyslipaemia, 8 and
123 for atrial fibrillation and 17 and 136 for thrombo-
embolic risk (totals: 202 and 2392). The clinical cases
covered the various clinical situations encountered in the
CPGs, and the various events that may be observed in
therapeutic histories, such as poor drug tolerance. These
tests were used during the development of the ASTI 3
critiquing module; at the end of the development, all tests
were passed without error.
Second, we generated decision trees for the diabetes
type 2, tobacco addiction, dyslipaemia, atrial fibrillation
and thrombo-embolic risk knowledge bases. In these
decision trees, each path is a patient profile (including
both clinical elements and therapeutic elements, such as
past treatment or drug intolerance) and leads to the list of
treatments that are not critiqued when prescribed to this
patient profile. We have already used such decision trees
in a previous study, for type 2 diabetes [19]; an excerpt of
a tree is shown in Additional file 3. The decision trees
were reviewed by the DSS designers, and they helped to
identify some errors in the knowledge bases. For instance,
in the dyslipaemia knowledge base, a recommendation
was stating that fibrates are less effective than statins;
however this is only true when treating hypercholestero-
laemia, but not other dyslipaemia such as hypertriglyceri-
daemia or hypoHDLaemia. We discovered the problem
on the tree, and we modified the recommendation by
adding hypercholesterolaemia to its condition.
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Hyp. Diab. Dys. Tob. Atr. Thr.
Modelled Number of pharmaco-therapeutic drug classes 7 7 10 5 11 3
CPG Number of recommended treatments 30 39 15 12 14 3
recommendations Number of "one should prescribe..." 
recommendations
30 14 9 7 6 6
Number of "one should not prescribe..." 
recommendations
19 10 6 11 4 1
Number of "treatments of increasing power..." 
recommendations
1 3 2 1 0 0
Total number of recommendations 50 27 17 19 10 7
Generated rules Number of "if ... then criticism" rules 119 102 73 42 51 16
Number of treatment patterns 826 1121 708 267 591 82
Hyp.: hypertension, Diab.: type 2 diabetes, Dys.: dyslipaemia, Tob.: tobacco addiction, Atr.: atrial fibrillation, Thr.: thrombo-embolic risk. User-
defined knowledge bases refer to the recommendations as entered into the system, and generated knowledge bases to the rule bases 
automatically generated by the system, including generic rules and after applying macros to transform all recommendations into "if 
conditions then criticism" rules.
Third, the six knowledge bases were reviewed by a phy-
sician. The format of the recommendations expressed in
the knowledge bases was clear to the physician. For
tobacco addiction, atrial fibrillation and thrombo-embo-
lic risk, the physician found that the knowledge bases
conformed to the content of the CPGs. For dyslipaemia,
the physician found two errors, related to the use of feno-
fibrate + statin bitherapy and the definition of the high
cardio-vascular risk for diabetic patients; these errors
have now been corrected in the knowledge base. For dia-
betes type 2, the evaluation led to three modifications: a
rule has been added for critiquing some sub-optimal
bitherapies, and the two rules for insulinotherapies have
been modified. For hypertension, the evaluation led to
three modifications: quadritherapies and alpha-blocker/
central antihypertensives have been allowed under cer-
tain circumstances, and diabetic patients with renal fail-
ure but without micro-albuminuria were not correctly
dealt with. In addition, the physician successfully discov-
ered some recommendations that were present in the
CPGs, but that were knowingly not implemented in the
knowledge bases, due to practical problems. For example,
the tobacco addiction CPG does not recommend hypno-
sis therapy, however this was not computerized because
hypnosis is not coded in the prescriptions of patients'
electronic record.
We also measured the system response time for the test
base. The system response time was short: about 200 mil-
liseconds for initializing and loading a knowledge base,
and then about 35 milliseconds for handling one case
(measured on a Pentium 4 processor at 2 GHz with 512
Mb).
Discussion
In this article, we have highlighted the importance of
translating the recommendations found in CPGs into "if
conditions then criticism" rules that can be used to criti-
cize physicians' activities during his/her practice; we also
describe algorithms to perform the translation automati-
cally from a structured model of CPG recommendations.
We propose eight generic recommendations, which are
guideline-independent but apply in many situations.
DSSs must take into account these generic recommenda-
tions, but as they are usually implicit in CPG writing
them is not easy. Finally, we describe a method for gener-
ating an appropriate textual critique to show to the physi-
cian. This task is not trivial because, as CPGs usually do
not contain information explaining why a treatment
should not be prescribed to a given patient, the existent
structured models of CPGs [27] do not represent this
information. In this paper, we propose a model of CPG
therapeutic recommendations that provides attributes for
representing the various elements of the textual critique.
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mendations that fit the CPG recommendation model into
"if conditions then criticism" rules, and this model was
able to structure all therapeutic recommendations found
in the five CPGs. Therefore, it is likely to be pertinent to
most or even all situations frequently encountered in gen-
eral practice. However, further evaluations should be per-
formed to determine if this model can be used as-is for
more complex or specific medical fields, such as oncol-
ogy. In particular, we did not take treatment durations
into account; however it would not be difficult to add a
duration attribute to the treatment model.
In addition, CPGs also include recommendations for
test ordering and diagnosis. Test ordering shares many
features with drug prescription, and a method similar to
the one we described could be used to criticize test order-
ing.
Some generic recommendations do not apply to all the
five CPGs, and especially the tobacco addiction CPG.
This is because tobacco addiction treatment is not a
chronic treatment: after the patient has stopped smoking,
the treatment can be discontinued. However, despite
these exceptions, the generic recommendations we pro-
pose sound logical to physicians and we think they can
apply in most situations. They can be considered as
default behaviour, until the CPG explicitly states the con-
trary.
The textual critiques generated explain why the treat-
ment proposed by the physician should not be pre-
scribed, provides recommendations for the patients, and
gives additional references. They are accompanied by a
list of suggestion for treatments. This critique structure
seems to cover both the information provided by the
guideline and the information expected by the physicians.
Most of the critiquing DSSs published in the literature
[9,12,14] are based on a list of manually written "if condi-
tions then criticism" rules. As stated in the introduction,
writing these knowledge bases is more complex than
structuring the CPG and then automatically generating
the "if conditions then criticism" rules, as we propose in
this article. J. van der Lei et al. [28] expressed a similar
opinion. To facilitate the creation of knowledge bases,
they recommended separating medical knowledge, i.e.
that found in the CPG, from the critiquing knowledge, i.e.
how to perform a critique using the medical knowledge.
In our architecture, the critiquing knowledge corre-
sponds to the algorithms translating the structured
model of the CPG recommendations into "if conditions
then criticism" rules.
A.M. Albisser et al. [29,31] proposed a critiquing DSS
for insulino-dependent diabetes, based on a simulator.
This simulator is able to predict how glycated hemoglo-
bin and risk of hypoglycemia evolves when the various
doses of insulin and oral antidiabetics are increased or
decreased. Such simulators are promising, but this
approach is disease-specific, since each disease would
require a specific simulator.
P. Groot et al. [32] also proposed a critiquing system
based on a CPG model; they used the Asbru format,
along with model checking. They also highlighted the dif-
ficulty of building human readable critiques, but they
only proposed a partial solution to this problem. Another
example of critiquing system using recommendations as a
knowledge base is the ISABEL system [33], which relies
on a set of textbook and native language processing tools
for producing reminders related to diagnosis.
Most of the efforts involved in designing the ASTI 3
critiquing module was spent on the design of the engine,
including the models and the algorithms. Then, imple-
menting the five CPGs was relatively easy, due to the sim-
ple CPG model, close to what is expressed in the
guideline, and the generic recommendations, which pro-
vide default behaviours for frequent tasks such as dealing
with doses. Finally, after the implementation of the diabe-
tes type 2 CPG, we had to update the knowledge base to
take into account recent developments in medical knowl-
edge related to the use of glitazones. This update led to
the modification of two rules in the knowledge base and
has been performed in a few hours work. Most of this
time was spent in updating the testing base and then test-
ing the system, to ensure that nothing was broken. Con-
sequently, we think that implementing and updating
CPGs in the ASTI 3 critiquing module can be quick and
practical. It would be interesting to carry out a more rig-
orous evaluation of the time required for implementing
new CPGs, and for updating an already implemented
CPG, and a more detailed assessment of any difficulties
encountered.
The ASTI 3 critiquing module could be improved by
adding support for the standard CPGs models published
in the literature [34], such as Proforma [35], Prodigy [36]
or GLIF [37]. This could be achieved by designing an
automatical tool to translate these models into the simple
CPG recommendation model we have proposed.
Despite its simplicity, our model can represent general
therapeutical structures similar to the ones used by the
standard CGP models. For example, a plan-based recom-
mendation composed of three plans: diet, monotherapy
and bitherapy, with the monotherapy plan including met-
formin as first-line treatment and AGI as second-line
treatment, can be represented in our model with nested
"one should prescribe" recommendations. It would lead
to the following recommendations: "one should prescribe
a diet as first-line treatment, a monotherapy as second-
line treatment and a bitherapy as third-line treatment"
and "if the proposed treatment is a monotherapy, then
one should prescribe metformin as first-line treatment
and AGI as second-line treatment".
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of such an automatic translation tool, is the generation of
the textual critics that are displayed to the physicians (i.e.
the "criticismLabel" attributes in figure 4). The standard
CPG models usually include the text of the CPG, how-
ever, as said previously, this text expresses recommenda-
tions but not critics, and therefore it may not be
appropriate for a critiquing system.
Our intention is now to improve the integration of the
ASTI critiquing module in EPR, using more user-friendly
dialog boxes and coding support tools, in order to make it
usable in real clinical situations. In addition, we plan to
integrate the critiquing module with various EPR soft-
ware, including éO Généraliste but not limited to this
particular software.
Conclusion
We have presented methods, including models and algo-
rithms, for critiquing physicians' prescriptions, using a
structured representation of the therapeutic parts of the
clinical guidelines. Therefore, writing additional knowl-
edge bases is straightforward, and is even facilitated by
the use of generic recommendations, i.e. pre-defined rec-
ommendations that apply to almost any guidelines. We
have also shown how to generate a textual critique that
explains why a non-recommended treatment should not
be prescribed. These methods have been successfully
applied in the ASTI 3 critiquing module, a decision sup-
port system which implements five clinical guidelines
related to cardiovascular risks. We are now planning to
evaluate ASTI 3, including the critiquing module, in a
randomized clinical trial, to determinate the impact of
the system on medical practices and patient outcomes.
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